As a consequence, the treatment of patients affected by melanoma with LMW-PTP inhibitors could induce a paradoxical effect, inhibiting on the one side, the proliferation of cancer cells, but on the other, impairing the immune response. The gene discussed is ACP1; the disease is melanoma.